Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Collaboration allows Philochem to secure access to ¹⁷⁷Lutetium N.C.A., a medical isotope used in multiple clinical trials for radiopharmaceutical therapies in areas of high unmet medical needs and CMO manufacturing for lead candidate

OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Under these agreements, Isotopia will supply high quality ¹⁷⁷ Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.

OncoFAP-23 is a novel small molecule ligand developed for Targeted Radionuclide Therapy which selectively binds to Fibroblast Activation Protein (FAP), an antigen expressed in a variety of solid human malignancies, while being undetectable in most healthy tissues. Philochem's scientists demonstrated that ¹⁷⁷Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other ¹⁷⁷Lu-FAP-ligands.

¹⁷⁷Lu n.c.a is used in Targeted Radionuclide Therapy in the field of Precision Medicine in Oncology. By binding n.c.a. ¹⁷⁷Lu isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of ¹⁷⁷Lu.  ¹⁷⁷Lu n.c.a contains no Mercury (Hg) and no metastable ¹⁷⁷Lu-m, therefore there is no need for cost intensive clinical waste management.

Seibersdorf's CEO, Martina Schwaiger stated: "The new agreement is a great opportunity for our team and we are pleased to be working with Philochem and Isotopia Molecular Imaging on this important sector of medical care." 

Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics. This collaboration is important to pursue Philochem's bench-to-bedside translational research, with competitive timelines, on our novel best-in-class ¹⁷⁷Lu-OncoFAP-23."

"This three-way collaboration demonstrates the ability to provide the full support for clinical development" stated Keren Moshkoviz, Director of Business Development at Isotopia. "Isotopia's aim is to play a significant role in early developments that will benefit patients in the future. We try to build a platform that can drive new products into the clinic in a simple and agile way.

We are excited to work with the Philochem and Seibersdorf Laboratories team to bring this product to the clinic ."

About Philochem and the Philogen Group
Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines, or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies.

Contact: Emanuele Puca \ Investor Relations                     
Tel: +41 (0) 43 544 88 00
Email: [email protected]                  
www.philochem.ch \ www.philogen.com

About Isotopia
Isotopia Molecular Imaging Ltd. is a dominant ¹⁷⁷Lu n.c.a supplier, its development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers, and physicists. The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, ¹⁷⁷Lu production site and sterile manufacturing plant, are a well-established platform for manufacturing and collaborations. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Contact: Keren Moshkoviz                          
Tel: +972 (54) 8182398   
Email: [email protected]                              
https://isotopia-global.com/                                  

About Seibersdorf Labor GmbH (Seibersdorf Laboratories)
Seibersdorf Labor GmbH is an Austrian company specialized in high quality laboratory and analysis work, application-oriented research and development as well as consulting and training.

The teams of Seibersdorf Laboratories are service, know-how and technology provider and cover a broad area of scientific expertise: development, production and quality control of radiopharmaceuticals, anti-doping and forensic analysis, radiation protection, ionizing and non-ionizing radiation, radio frequency engineering and electromagnetic compatibility. The experts of Seibersdorf Laboratories represent Austria on various international committees.

Contact: Roland Müller \ Head Pharmaceuticals
Tel: +43 50 550 3470
Email: [email protected]
www.seibersdorf-laboratories.at

SOURCE Isotopia; Philochem AG; Seibersdorf Labor GmbH